重症新生儿肺透明膜病肺表面活性物质替代治疗

Pulmonary surfactant replacement therapy for severe pulmonary hyaline membrane disease in neonates

探讨外源性肺表面活性物质治疗重症新生儿肺透明膜病（HMD）的疗效。方法对重症HMD病儿于生后气管内给药，观察用药后临床表现、血气结果、肺部X线以及并发症的变化。结果33例中30例给药后即刻症状和体征改善，血气分析结果明显好转；给药3d内肺部X线23例有明显改善；33例中16例存活，其中9例有严重并发症。结论外源性肺表面活性物质对重症HMD有肯定疗效，在改善氧气交换和肺部病变方面发挥重要作用。

To probe into the therapeutic effectiveness of exogenous pulmonary surfactant upon severe pulmonary hyaline membrane disease in neonates.Methods Administer exogenous pulmonary surfactant to neonates with severe pulmonary hyaline membrane disease, through trachea after birth,then observe the changes of clinical manifestations, the results of blood gas, X-ray presentations in lungs, and complications after administration.Results After administration. the symptoms and signs of 30 out of 33 patients were improved immediately. The results of blood gas analysis were also improved and X-ray presentations of 23 patients were turned better. 16 patients survived. but 9 patients had severe complications.Cobclusion Exogenous pulmonary surfacfant has definite effect on severe pulmonary hyaline membrane disease and plays an important role in improving oxygen exchange and pathological changes in lungs.